Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.63 |
| ▸ | MTNR1A | P48039 | 11/20 | 0.60 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.60 |
| ▸ | NQO2 | P16083 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29421589 | 1.00 | LMNA (0.63) | LMNAALDH1A1HPGDNPSR1RXFP1 | |
| SCHEMBL16797980 | 0.84 | MTNR1A (0.71) | MTNR1AMTNR1BNQO2HTR2AHTR2C | |
| SCHEMBL3242823 | 0.81 | MAPT (0.57) | ALDH1A1HPGDMEN1MAPTKMT2A | |
| SCHEMBL14479196 | 0.81 | GAA (0.46) | LMNAALDH1A1HPGDNPSR1RXFP1 | |
| SCHEMBL8616007 | 0.80 | MTNR1A (0.53) | ALDH1A1MTNR1AMTNR1BNQO2HTR2A | |
| SCHEMBL27366827 | 0.80 | MTNR1B (0.56) | LMNAALDH1A1HPGDNPSR1RXFP1 | |
| SCHEMBL31331827 | 0.80 | MTNR1B (0.56) | LMNAALDH1A1HPGDNPSR1RXFP1 | |
| SCHEMBL8229566 | 0.78 | MAPT (0.87) | LMNAALDH1A1HPGDNPSR1RXFP1 | |
| SCHEMBL6965415 | 0.77 | NR1H2 (0.67) | LMNAALDH1A1HPGDNPSR1RXFP1 | |
| SCHEMBL9282955 | 0.76 | HTR1A (0.62) | ALDH1A1HPGDMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653281-B2 | Process for the manufacture of agomelatine and its intermediate | NHWA PHARMA. CORPORATION (CN) | 2014-02-18 | — | — | US | claimed |
| EP-2322508-B1 | PROCESS FOR THE MANUFACTURE OF AGOMELATINE AND ITS INTERMEDIATE | NHWA PHARMA CORP (CN) | 2013-01-02 | — | — | EP | claimed |
| US-20120245363-A1 | PROCESS FOR THE SYNTHESIS OF AGOMELATINE | LES LABORATOIRES SERVIER (FR) | 2012-09-27 | — | — | US | claimed |
| EP-2151428-B1 | Process for the preparation of agomelatin | SERVIER LAB (FR) | 2012-03-07 | — | — | EP | claimed |
| US-20110130571-A1 | PROCESS FOR THE MANUFACTURE OF AGOMELATINE AND ITS INTERMEDIATE | NHWA PHARMA. CORPORATION (CN) | 2011-06-02 | — | — | US | claimed |
| EP-2322508-A1 | PROCESS FOR THE MANUFACTURE OF AGOMELATINE AND ITS INTERMEDIATE | NHWA Pharma. Corporation (CN) | 2011-05-18 | — | — | EP | claimed |
| CN-117776934-A | Preparation method of agomelatine intermediate | 江苏威奇达药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-215962353-U | Filter equipment is used in synthesis of agomelatine | 河南华商药业有限公司 | 2022-03-08 | — | — | CN | disclosed |
| WO-2016046833-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF AGOMELATINE USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2016-03-31 | — | — | WO | disclosed |
| WO-2014064706-A1 | PROCESSES FOR THE PREPARATION OF AGOMELATINE USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2014-05-01 | — | — | WO | disclosed |
| EP-2703383-A1 | Process for the preparation of agomelatine | Procos S.p.A. (IT) | 2014-03-05 | — | — | EP | disclosed |
| US-8653281-B2 | Process for the manufacture of agomelatine and its intermediate | NHWA PHARMA. CORPORATION (CN) | 2014-02-18 | — | — | US | disclosed |
| US-8653281-B2 | Process for the manufacture of agomelatine and its intermediate | NHWA PHARMA. CORPORATION (CN) | 2014-02-18 | — | — | US | disclosed |
| EP-2322508-A1 | PROCESS FOR THE MANUFACTURE OF AGOMELATINE AND ITS INTERMEDIATE | NHWA Pharma. Corporation (CN) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322508-A1 | PROCESS FOR THE MANUFACTURE OF AGOMELATINE AND ITS INTERMEDIATE | NHWA Pharma. Corporation (CN) | 2011-05-18 | — | — | EP | disclosed |
| CN-101638376-B | Method for preparing agomelatine and intermediate of agomelatine | JIANGSU NHUA PHARMACEUTICAL CO LTD | 2011-04-27 | — | — | CN | disclosed |
| US-20100036162-A1 | Process for the synthesis of agomelatine | LES LABORATOIRES SERVIER (FR) | 2010-02-11 | — | — | US | disclosed |
| EP-2151428-A1 | Process for the preparation of agomelatin | Les Laboratoires Servier (FR) | 2010-02-10 | — | — | EP | disclosed |
| WO-2010012208-A1 | PROCESS FOR THE MANUFACTURE OF AGOMELATINE AND ITS INTERMEDIATE | 江苏恩华药业股份有限公司 (CN) | 2010-02-04 | — | — | WO | disclosed |
| CN-101638376-A | Method for preparing agomelatine and intermediate of agomelatine | JIANGSU NHUA PHARMACEUTICAL CO | 2010-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130571-A1 | PROCESS FOR THE MANUFACTURE OF AGOMELATINE AND ITS INTERMEDIATE | PNMT, INMT, PTMA | LMNA 2190/4885ALDH1A1 94/4885HPGD 3377/4885 |
| US-20120245363-A1 | PROCESS FOR THE SYNTHESIS OF AGOMELATINE | COMT, PNMT, TPH1 | LMNA 3618/4885ALDH1A1 1161/4885HPGD 1187/4885 |
| US-20100036162-A1 | Process for the synthesis of agomelatine | COMT, PNMT, TPH1 | LMNA 3618/4885ALDH1A1 1161/4885HPGD 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.